Key Takeaway: RenovoRx Inc. has successfully treated its first patient in a clinical trial for its FDA-cleared drug delivery device, RenovoCath, at the University of Vermont Cancer Center. The trial has expanded to include Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center as additional sites. The study is led by notable principal investigators from these institutions.
Price reaction · baseline $0.9962 (2025-11-10 close) · hit after-hours · 1 other RNXT headline(s) in the window, move may be shared
day 0 close
+7.4%
day 1
+0.4%
day 3 · peak
-24.7%
Market Sentiment Analysis
POSITIVE FACTORS
First patient treated successfully in the clinical trial.
RenovoCath device is FDA-cleared, indicating regulatory confidence.
Multiple prestigious cancer centers are participating in the study.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer
Full Press Release Details
RenovoRx Inc.’s study of its U.S. Food and Drug Administration (FDA)-cleared drug delivery device, RenovoCath, has marked a major milestone with the first patient treatment at the University of Vermont Cancer Center.
RenovoRx also announced that Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the University of Vermont Cancer Center as participating clinical sites in the PanTheR registry study. Principal investigators at the first three PanTheR clinical sites include Dr. Ripal Gandhi, interventional radiologist at Baptist Health Miami Cancer Institute; Dr. Paula Novelli, interventional radiologist at University of Pittsburgh Medical Center; and Dr. Conor O’Neill, surgical oncologist at the University of Vermont Cancer Center. The study began at the University of Vermont Cancer Center with Dr. O’Neill’s team; the additional two sites are expected to initiate patient procedures soon.
Read the full article on M edical Product Outsourcing
Frequently Asked Questions
What is RenovoCath?
RenovoCath is a drug delivery device developed by RenovoRx, which has received FDA clearance.
Where was the first patient treated?
The first patient was treated at the University of Vermont Cancer Center.
Which centers are participating in the study?
Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center are participating.
Who are the principal investigators?
Dr. Ripal Gandhi, Dr. Paula Novelli, and Dr. Conor O'Neill are the principal investigators.